Renata Sano

715 total citations
8 papers, 413 citations indexed

About

Renata Sano is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Renata Sano has authored 8 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 6 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Renata Sano's work include Neuroblastoma Research and Treatments (7 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Renata Sano is often cited by papers focused on Neuroblastoma Research and Treatments (7 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Renata Sano collaborates with scholars based in United States, New Zealand and Italy. Renata Sano's co-authors include Ida Annunziata, Alessandra d’Azzo, Kateryna Krytska, Yaël P. Mossé, Nicole R. Infarinato, Hannah T. Ryles, Pichai Raman, Jin H. Park, Nathan V. Lee and Helen Y. Zou and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Science Translational Medicine.

In The Last Decade

Renata Sano

8 papers receiving 409 citations

Peers

Countries citing papers authored by Renata Sano

Since Specialization

Citations

This map shows the geographic impact of Renata Sano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renata Sano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renata Sano more than expected).

Fields of papers citing papers by Renata Sano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renata Sano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renata Sano. The network helps show where Renata Sano may publish in the future.

Co-authorship network of co-authors of Renata Sano

This figure shows the co-authorship network connecting the top 25 collaborators of Renata Sano. A scholar is included among the top collaborators of Renata Sano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renata Sano. Renata Sano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma 2021 ·Molecular Cancer Therapeutics ·(unknown), Kateryna Krytska, Timothy L. Lochmann, Renata Sano, (unknown), (unknown), Qasim A. Khan, (unknown), (unknown), Jinyang Cai, Sheeba Jacob, Richard Kurupi, Bin Hu, Mikhail G. Dozmorov, Patricia Greninger, Andrew J. Souers, Cyril H. Benes, Yaël P. Mossé, Anthony C. Faber	13
2	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma 2019 ·Science Translational Medicine ·Renata Sano, Kateryna Krytska, (unknown), Pichai Raman, Daniel Martínez, Gwenda F. Ligon, Jay S. Lillquist, Ulisse Cucchi, Paolo Orsini, Simona Rizzi, Bruce Pawel, Diego Alvarado, Yaël P. Mossé	45
3	Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases 2018 ·Cell Death and Disease ·Ida Annunziata, Renata Sano, Alessandra d’Azzo	90
4	Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma 2018 ·Cancer Research ·Renata Sano, Kateryna Krytska, (unknown), Stephen W. Erickson, Beverly A. Teicher, Laura R. Saunders, Ryan Jones, (unknown), John M. Maris, Yaël P. Mossé	5
5	Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma 2016 ·Clinical Cancer Research ·Andrew Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, (unknown), Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You He, Shiva Krupa, Nanxin Li, Jennifer L. Harris, Yaël P. Mossé	67
6	Abstract 2690: A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma 2016 ·Cancer Research ·Renata Sano, Kateryna Krytska, (unknown), Gwenda F. Ligon, Jay S. Lillquist, Ulisse Cucchi, Paolo Orsini, Simona Rizzi, Gerald McMahon, Diego Alvarado, Yaël P. Mossé	1
7	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma 2015 ·Cancer Discovery ·Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Renata Sano, (unknown), Yimei Li, Helen Y. Zou, Nathan V. Lee, Tod Smeal, Mark A. Lemmon, Yaël P. Mossé	116
8	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma 2015 ·Clinical Cancer Research ·Kateryna Krytska, Hannah T. Ryles, Renata Sano, Pichai Raman, Nicole R. Infarinato, (unknown), Monish Ram Makena, Michael M. Song, C. Patrick Reynolds, Yaël P. Mossé	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact